Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders GlobeNewswire - Fri Jul 24, 4:00PM CDT

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes GlobeNewswire - Tue Jun 30, 3:15PM CDT

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 4:00PM CDT

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.25 (+1.98%)
MarketBeat.com
Pelthos Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 15, 7:12PM CDT

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch, executives...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics Announces First Quarter 2026 Financial Results GlobeNewswire - Thu May 14, 6:00AM CDT

 ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 GlobeNewswire - Fri May 1, 7:30AM CDT

DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium GlobeNewswire - Tue Apr 14, 7:30AM CDT

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics Announces CFO Transition GlobeNewswire - Fri Apr 10, 4:00PM CDT

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain GlobeNewswire - Tue Mar 31, 7:30AM CDT

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

PTHS : 26.25 (+1.98%)
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Mar 19, 5:30AM CDT

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...

PTHS : 26.25 (+1.98%)

Barchart Exclusives

Here’s Why Verizon Stock Is a Buy for Income Investors in August Barchart - Thu Jul 30, 6:30PM CDT
A safer dividend, stronger free cash flow, and new growth opportunities make Verizon increasingly attractive for income-focused investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.